JAMA · 1995 · 49 citations · 3 references
MedicineEndocrinologyOncologyCancer EpidemiologyEpidemiologic MethodsMeta-analysisAdjuvant TherapyBreast Cancer Risk AssessmentClinical TrialsHormonal Cancer TherapyHormonal TherapyMenopause Hormone TherapyBreast Cancer Hormonal TherapyBreast Cancer Hormone TherapyCase-control Association StudiesPostmenopausal Hormone TherapyType Ii ErrorType Ii Error AnalysisType Ii Error Rate
<h3>In Reply.</h3> —We thank the many authors of letters written in response to our work. Meta-analyses, which overcome type II error, have not demonstrated an association between ERT and risk of breast cancer. In general, prospective studies are preferable to case-control studies. However, there are problems with all studies, including prospective ones. For example, the Nurses' Health Study found an increase in breast cancer risk only in those who were drinking alcohol.<sup>1</sup>The Swedish study wasn't a true prospective cohort trial.<sup>2</sup>Files from a prescription database were merged with files from a cancer registry. It is not known whether "hormone users" were actually taking hormones. We need to weigh the entire body of evidence. We should not discount the results of 25 case-control studies because we think two prospective ones are better. Most studies of adjuvant tamoxifen in postmenopausal women evaluated tamoxifen vs no treatment, whereas those in
3
The Risk of Breast Cancer after Estrogen and Estrogen–Progestin Replacement
Leif Bergkvist, Hans‐Olov Adami, Ingemar Persson et al. · New England Journal of Medicine · 1989 · 619 citations
Medicine, Endocrinology, Oncology +13